Baird ‘encouraged’ by Vor Bio’s early engraftment, protective data from trem-cel

Baird analyst Jack Allen notes that Vor Bio announced initial data from the first patient treated with trem-cel, the company’s novel CD33Del HSCT. Notable, Allen is "encouraged" to see that trem-cel engraftment was robust occurring on a similar time course to un-engineered HSCTs and that post-Mylotarg the patient did not exhibit neutropenia or increases in LFTs, providing early evidence of a broadening of the therapeutic window. All told, the analyst is "very encouraged" by this initial proof-of-concept of Vor’s approach, and expects investor enthusiasm for this program to build as the dataset grows. Allen has an Outperform rating on the shares with a price target of $38.